Sector News

Ferro appoints Benjamin Schlater as VP and CFO

September 5, 2016
Life sciences

Ferro Corp. (FOE) said that Benjamin Schlater, who has served as Ferro’s Vice President, Corporate Development and Strategy since September 2015, has been named Vice President and Chief Financial Officer, succeeding Jeffrey Rutherford, who stepped down from the position on September 1.

James Barna, Ferro’s Corporate Controller, has been appointed to the additional role of Chief Accounting Officer of the Company.

Lori Saviers, who was Ferro’s Chief Procurement Officer, has been named Vice President, Sourcing and Global Supply Chain. In addition, Sandy Frydryk has been named Director, Corporate Development and Integration.

Rutherford is expected to remain with the Company as an advisor to Schlater through the end of 2016 to ensure a smooth transition of responsibilities.

Schlater joined Ferro in September 2015. He has nearly 20 years of corporate finance experience. His experience includes serving as treasurer and head of corporate development, strategic and financial planning, and risk management at Veyance Technologies, a $2 billion global manufacturing company then owned by The Carlyle Group. Prior to Veyance, he was a managing director at FTI Consulting. Prior to that, he was a manager at PricewaterhouseCoopers in its corporate finance practice.

Source: RTT News

comments closed

Related News

October 1, 2023

Clinical data from Boston Scientific and rivals could reshape pulmonary embolism market: analysts

Life sciences

After attending the annual Pulmonary Embolism Symposium last week in Austin, Texas, the analysts predicted clinical guidelines could shift toward catheter-based therapy once data from ongoing randomized trials is available.

October 1, 2023

AstraZeneca and SAS link up on AI and analytics

Life sciences

SAS – the AI and analytics company – has been selected by AstraZeneca to help boost efficiency and drive automation in the delivery of statistical analyses for clinical and post-approval submissions to regulatory authorities.

October 1, 2023

Will Big Pharma engage in Medicare price negotiations? Merck, AZ and BMS say they will

Life sciences

After the Centers for Medicare & Medicaid Services (CMS) revealed the list of drugs set to face the first round of price negotiations under the Inflation Reduction Act (IRA), the drugmakers responsible for marketing them are confronting a series of deadlines.

How can we help you?

We're easy to reach